Alto Neuroscience, Inc. (ANRO) is a Healthcare · Biotechnology company listed on NYSE. Price $30.50 (-1.55%), Market cap $0.77B, 52-week low–high $2.20 ~ $27.72.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 recep
Financial statements, price targets, institutional (13F) holdings and related news for Alto Neuroscience, Inc. are updated in real time on BlackAll Trade.
Alto Neuroscience, Inc. trades at $30.50 (-1.55%). Real-time quotes and charts are available on BlackAll Trade.
Alto Neuroscience, Inc. has a market cap of about $0.77B.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treat